bullish
GLP-1 Drugs – Are They Dessert or Time Bomb to Your Portfolio?
463 Views16 Oct 2023 08:55
GLP-1s will be the next major opportunity in healthcare, which won't be limited to weight loss drugs. But when they expand new indications, they will inevitably hit the development of other industries
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Gushengtang (2273.HK) - 2023 Full-Year Performance Would Exceed Expectations23 Oct 2023
- China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine22 Oct 2023
- Asymchem Laboratories (6821.HK/002821.CH) - A Heartening Rise in Share Price Could Be Drawing Near17 Oct 2023
- GLP-1 Drugs – Are They Dessert or Time Bomb to Your Portfolio?16 Oct 2023
- Ping An Healthcare and Technology (1833.HK) - Valuation Could Fall Again Due to Clear Growth Ceiling12 Oct 2023
- WuXi AppTec (2359.HK/603259.CH) - Would the Recent Rebound in Share Price Be a Flash in the Pan?10 Oct 2023
- China's Weight Loss Drug Market – The Investment Opportunities and the Risks Behind09 Oct 2023
x